Our website uses cookies to enable essential features and improve your browsing experience. Additionally, cookies enhance overall website functionality and user experience. By choosing I Accept, you agree to our use of non-essential cookies and other tracking technologies.

You have the ability to manage your settings or withdraw your consent at any time. We are committed to maintaining the privacy and security of your personal information. For detailed information on how we use cookies, including how to manage your privacy and preferences, please visit our cookie policy .
Developmentaid logo
Register
Print
Print
Gates Foundation

Global: To isolate novel GH drugs from bacteria by mining biosynthetic gene clusters associated with self-resistance genes leading to new drugs to benefit those in the developing world infected with global health pathogens, such as TB and malaria

Last update: 1 day ago Last update: Apr 17, 2026

Details

Locations:Canada
Start Date:Sep, 2022
End Date:Jun, 2024
Contract value: USD 1,237,639
Sectors:Health, Research & Innovation
 Health, Research & Innovation
Categories:Grants
Funding Agencies:
Gates Foundation
Date posted:Apr 17, 2026
Contracting authority:Gates Foundation

Associated funding

Associated experts

Description

Purpose: To isolate novel GH drugs from bacteria by mining biosynthetic gene clusters associated with self-resistance genes leading to new drugs to benefit those in the developing world infected with global health pathogens, such as TB and malaria
Division: Global Health
Region served: GLOBAL
Grant topic: Create Novel Technology Platform Capabilities
Duration (months): 21
Grantee location: Hamilton, Ontario, Canada

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.
Learn more about our membership benefits
Print